Last reviewed · How we verify
FluBHPVE6E7
At a glance
| Generic name | FluBHPVE6E7 |
|---|---|
| Also known as | Placebo |
| Sponsor | BlueSky Immunotherapies GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women (PHASE1)
- BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
- Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer (PHASE1)
- Study of FluBHPVE6E7 in HPV-16 Infected Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluBHPVE6E7 CI brief — competitive landscape report
- FluBHPVE6E7 updates RSS · CI watch RSS
- BlueSky Immunotherapies GmbH portfolio CI